These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 15830142

  • 1. Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A.
    Langenheim JF, Chen WY.
    Breast Cancer Res Treat; 2005 Apr; 90(3):281-93. PubMed ID: 15830142
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells.
    Cataldo L, Chen NY, Yuan Q, Li W, Ramamoorthy P, Wagner TE, Sticca RP, Chen WY.
    Int J Oncol; 2000 Dec; 17(6):1179-85. PubMed ID: 11078803
    [Abstract] [Full Text] [Related]

  • 3. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation.
    Llovera M, Pichard C, Bernichtein S, Jeay S, Touraine P, Kelly PA, Goffin V.
    Oncogene; 2000 Sep 28; 19(41):4695-705. PubMed ID: 11032019
    [Abstract] [Full Text] [Related]

  • 4. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
    Beck MT, Chen NY, Franek KJ, Chen WY.
    Cancer Res; 2003 Jul 01; 63(13):3598-604. PubMed ID: 12839947
    [Abstract] [Full Text] [Related]

  • 5. A novel design of targeted endocrine and cytokine therapy for breast cancer.
    Zhang G, Li W, Holle L, Chen N, Chen WY.
    Clin Cancer Res; 2002 Apr 01; 8(4):1196-205. PubMed ID: 11948133
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R.
    Beck MT, Peirce SK, Chen WY.
    Oncogene; 2002 Aug 01; 21(33):5047-55. PubMed ID: 12140755
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
    Scotti ML, Langenheim JF, Tomblyn S, Springs AE, Chen WY.
    Breast Cancer Res Treat; 2008 Sep 01; 111(2):241-50. PubMed ID: 17955362
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Stromal-epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer.
    Xu C, Langenheim JF, Chen WY.
    Breast Cancer Res Treat; 2012 Jul 01; 134(1):157-69. PubMed ID: 22270933
    [Abstract] [Full Text] [Related]

  • 16. Novel reagents for human prolactin research: large-scale preparation and characterization of prolactin receptor extracellular domain, non-pegylated and pegylated prolactin and prolactin receptor antagonist.
    Oclon E, Solomon G, Hayouka Z, Salame TM, Goffin V, Gertler A.
    Protein Eng Des Sel; 2018 Jan 01; 31(1):7-16. PubMed ID: 29281090
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.